17.02.2017
BB BIOTECH AG CH0038389992
DGAP-News: BB BIOTECH AG: Annual report 2016
DGAP-News: BB BIOTECH AG / Key word(s): Final Results
BB BIOTECH AG: Annual report 2016 (news with additional features)
17.02.2017 / 07:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Media release as of February 17, 2017
Annual report of BB Biotech AG as of December 31, 2016
BB Biotech AG publishes its 2016 annual report
BB Biotech AG published its annual report for fiscal 2016 today. Besides
the audited consolidated financial statements, the annual report contains
detailed information on the biotechnology sector, BB Biotech's positioning,
the therapeutic areas covered by its portfolio and the
companies it is invested in.
As disclosed in the report, BB Biotech ended the year with a slightly
positive total return of 0.3% in CHF and 1.9% in EUR despite the
considerable difficulties the past year posed for biotech investors. Its
Net Asset Value (NAV) declined by 19.1% in CHF, 17.6% in EUR and 20.6% in
USD, which was somewhat better than the benchmark Nasdaq Biotech Index. The
performance of BB Biotech's shares in 2016 largely reflects the dissolution
of the discount to NAV. The consolidated and audited accounts show a net
loss of CHF 802 mn for fiscal 2016 compared to a net profit of CHF 653 mn
in the previous year.
As already announced on January 20, 2017, BB Biotech will propose an
ordinary dividend of CHF 2.75 per share at the upcoming Annual General
Meeting, which represents a yield of 5% based on the volume-weighted
average price of BB Biotech shares in December 2016. This marks a
continuation of the dividend policy as introduced in 2013.
BB Biotech's annual report 2016 can be downloaded at www.bbbiotech.com.
For further information:
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
Tel. +41 44 267 67 00
Dr. Silvia Schanz, [email protected]
Maria-Grazia Iten-Alderuccio, [email protected]
Claude Mikkelsen, [email protected]
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
Tel. +41 44 267 67 00
Tanja Chicherio, [email protected]
b-public AG, Pfingstweidstrasse 6, 8005 Zurich, Switzerland, Tel. +41 79
423 22 28
Thomas Egger, [email protected]
www.bbbiotech.com
Company profile
BB BIOTECH invests in companies in the fast-growing market of biotechnology
and is one of the world's largest investors in this sector. BB Biotech is
listed in Switzerland, Germany and Italy. Its investments are focused on
listed companies that are developing and commercializing novel medical
treatments and cures. BB Biotech's investment selection process is guided
by the fundamental research and analysis of physicians and molecular
biologists. Its Board of Directors has many years of experience in industry
and science.
Disclaimer
This release contains forward-looking statements and expectations as well
as assessments, beliefs and assumptions. Such statements are based on the
current expectations of BB Biotech, its directors and officers, and are,
therefore, subject to risks and uncertainties that may change over time. As
actual developments may significantly differ, BB Biotech and its directors
and officers accept no responsibility in that regard. All forward-looking
statements included in this release are made only as of the date of this
release and BB Biotech and its directors and officers assume no obligation
to update any forward-looking statements as a result of new information,
future events or other factors.
---------------------------------------------------------------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=EPVMJUYHCL
Document title: Media release
---------------------------------------------------------------------------
17.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
Fax: +41 1 267 67 01
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; SIX
End of News DGAP News Service
---------------------------------------------------------------------------
545123 17.02.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
BB BIOTECH AG ISIN: CH0038389992 können Sie bei EQS abrufen
Biotechnologie , A0NFN3 , BBZA , XETR:BBZA